Department of Orthopedics, Shanghai Tenth People's Hospital, Tongji University, School of Medicine, Shanghai 200072, PR China; Institute of Bone Tumor, Tongji University, School of Medicine, Shanghai 200072, PR China.
Department of Orthopedics, Shanghai Tenth People's Hospital, Tongji University, School of Medicine, Shanghai 200072, PR China; Institute of Bone Tumor, Tongji University, School of Medicine, Shanghai 200072, PR China.
Mol Ther. 2019 Mar 6;27(3):518-530. doi: 10.1016/j.ymthe.2019.01.001. Epub 2019 Jan 7.
Chemo-resistance is a huge obstacle encountered in the osteosarcoma (OS) treatment. Protein-coding mRNAs, as well as non-coding RNAs (ncRNAs), including long ncRNA (lncRNA), circular RNA (circRNA), and microRNA (miRNA), have been demonstrated to play an essential role in the regulation of cancer biology. However, the comprehensive expression profile and competing endogenous RNA (ceRNA) regulatory network between mRNAs and ncRNAs in the OS chemo-resistance still remain unclear. In the current study, we developed whole-transcriptome sequencing (RNA sequencing [RNA-seq]) in the three paired multi-drug chemo-resistant and chemo-sensitive OS cell lines to comprehensively identify differentially expressed lncRNAs, circRNAs, miRNAs, and mRNAs. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses were performed for mRNAs with significantly different expression. Then the ceRNA networks combining lncRNAs, circRNAs, miRNAs, and mRNAs were predicted and constructed on the basis of the authoritative miRanda and TargetScan databases combined with the widely accepted vital drug resistance-related genes and signal transduction pathways. In addition, two constructed ceRNA regulatory pathways, lncRNAMEG3/hsa-miR-200b-3p/AKT2 and hsa_circ_0001258/hsa-miR-744-3p/GSTM2, were randomly selected and validated by real-time qPCR, RNA immunoprecipitation (RIP), RNA pull-down assay, and dual luciferase reporter gene system. Taken together, our findings may provide new evidence for the underlying mechanism of OS chemo-resistance and uncover some novel targets for reversing it.
化疗耐药性是骨肉瘤 (OS) 治疗中遇到的巨大障碍。蛋白质编码的 mRNA 以及非编码 RNA(ncRNA),包括长链非编码 RNA(lncRNA)、环状 RNA(circRNA)和 microRNA(miRNA),已被证明在癌症生物学调控中发挥着重要作用。然而,在 OS 化疗耐药性中,mRNA 和 ncRNA 之间的综合表达谱和竞争性内源性 RNA(ceRNA)调控网络仍不清楚。在本研究中,我们在三对多药化疗耐药和化疗敏感的 OS 细胞系中开发了全转录组测序(RNA 测序 [RNA-seq]),以全面鉴定差异表达的 lncRNA、circRNA、miRNA 和 mRNA。对差异表达 mRNA 进行基因本体论 (GO) 和京都基因与基因组百科全书 (KEGG) 通路分析。然后,基于权威的 miRanda 和 TargetScan 数据库,并结合广泛接受的重要耐药相关基因和信号转导通路,预测和构建包含 lncRNA、circRNA、miRNA 和 mRNA 的 ceRNA 网络。此外,随机选择并通过实时 qPCR、RNA 免疫沉淀 (RIP)、RNA 下拉测定和双荧光素酶报告基因系统验证构建的两个 ceRNA 调控通路,lncRNAMEG3/hsa-miR-200b-3p/AKT2 和 hsa_circ_0001258/hsa-miR-744-3p/GSTM2。总之,我们的研究结果可能为 OS 化疗耐药的潜在机制提供新的证据,并揭示一些逆转耐药的新靶点。